Overview
Coverage is not a simple yes/no: it depends on which drug, which FDA-approved indication it's prescribed for, and which specific insurance plan the patient has. GLP-1 drugs used for their original FDA-approved indication (type 2 diabetes, e.g. Ozempic, Mounjaro) are far more likely to be covered than the same molecules marketed for weight loss (Wegovy, Zepbound), because many payers—most notably traditional Medicare—have historically excluded 'drugs used for weight loss' as a category regardless of FDA approval. Medicaid coverage of anti-obesity GLP-1s is state-optional and currently offered by only a minority of states, while commercial/employer plans set their own formulary tiers, prior-authorization criteria (e.g., BMI thresholds, documented lifestyle program participation), and step-therapy rules. Even where covered, cost-sharing, tiering, and utilization management can still make out-of-pocket costs significant.
Key Points
- Medicare has been statutorily prohibited from covering drugs used for weight loss under Part D since the Medicare Modernization Act of 2003 created this exclusion when the program launched in 2006. [7]
- Starting July 1, 2026, Medicare's new 'GLP-1 Bridge' program covers Foundayo, Wegovy, and Zepbound (KwikPen only) specifically for weight reduction for eligible beneficiaries, the first time Medicare has paid toward weight loss itself. [2]
- Under the Medicare GLP-1 Bridge program, eligible beneficiaries pay about $50 for each 30-day supply of a covered GLP-1 drug, and their doctor must certify the drug is being used as part of a diet-and-exercise lifestyle program, with prior authorization required when requested. [3]
- Medicare Part D already covers GLP-1 drugs such as Ozempic, Mounjaro, Rybelsus, and Trulicity when prescribed for type 2 diabetes, and covers Wegovy for cardiovascular risk reduction, separately from the new weight-loss-specific Bridge program. [6]
- Medicaid coverage of GLP-1 drugs for FDA-approved indications other than obesity is required, but coverage of GLP-1s specifically for obesity is optional for states, and only 13 states provided that obesity coverage as of January 2026, down from 16 states in 2025. [5]
- CMS's BALANCE Model lets participating state Medicaid programs (and eventually Part D plan sponsors) adopt standardized GLP-1 coverage criteria negotiated with drugmakers, but states must sign a formal agreement with CMS to participate, so it does not create automatic nationwide coverage. [5]
- A 2024 proposed federal rule to reinterpret Medicare's weight-loss exclusion so GLP-1 drugs could be covered for beneficiaries with obesity was projected to make as many as 13.7 million Medicare beneficiaries newly eligible, illustrating how large the pre-existing coverage gap was. [1]
- Employer-sponsored and other commercial health plans each set their own formulary tiers and prior-authorization or step-therapy requirements for GLP-1 weight-loss drugs, so whether Wegovy or Zepbound is covered — and at what cost-sharing level — varies significantly from plan to plan even when the drug is FDA-approved for weight management. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)